|
2000
|
|
|
2001
|
- Contura’s product Aquamid® granted the CE-marking for use in soft tissue facial augmentation
|
|
2003
|
- Contura’s product Bulkamid® granted the CE-marking for use in the treatment of female urinary incontinence
|
|
2004
|
- Contura launches Aquamid® Reconstruction for lipoatrophy, rhinoplasty and volume corrections
|
|
2005
|
- Contura achieves strong market positions in several Asian markets
|
|
2006
|
- FDA grants Aquamid® Investigational Device Exemption, allowing its use in a major comparative clinical trial in the United States
- Contura obtains ISO 13485:2003 and ISO 9001:2000 certificates.
|
|
2007
|
- Contura and ETHICON, a Johnson & Johnson company, sign agreement granting ETHICON exclusive worldwide distribution rights for Bulkamid®
- Contura’s United States subsidiary Contura Inc. established
- Work begins on a new manufacturing facility in Denmark
- Contura awarded the prestigious Product Differentiation Innovation Award for Aquamid® by the international consulting company Frost & Sullivan
|
|
2008
|
- Clinical trial of Bulkamid® in the United States begins
|
|
2009
|
- Clinical trial of Aquamid® in the United States completed
|
|
2010
|
- New manufacturing facility approved in Europe
- Aquamid® PMA filed at the FDA on April 15th
|
